GlassScriptPhysician profile
Raymond Knisley
NPI 1932189008
$2,711.09
in general payments reported to CMS, 2019-2025
29 companies · $619 in 2025
The $619 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $220 · 2020: $48.28 · 2021: $112 · 2022: $175 · 2023: $656 · 2024: $882 · 2025: $619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,974 · Education: $182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,974.46 |
| Education | $182.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $632.50 | 2019-2025 | Tremfya |
| Kerecis Limited | $534.10 | 2023-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
| Organogenesis INC. | $243.76 | 2023-2024 | Puraply, Novachor |
| Leo Pharma INC. | $201.77 | 2019-2023 | Adbry |
| Lilly USA, LLC | $139.62 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $117.42 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $103.98 | 2023-2024 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $97.91 | 2025 | Dupixent, Libtayo |
| Janssen Scientific Affairs, LLC | $94.05 | 2019 | |
| Pfizer INC. | $58.47 | 2021-2023 | |
| Galderma Laboratories, L.P. | $45.86 | 2022-2025 | Nemluvio |
| Abbvie INC. | $43.26 | 2021 | |
| Biofrontera INC. | $40.66 | 2019-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Mayne Pharma Commercial LLC | $36.75 | 2020-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $31.93 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $28.70 | 2025 | Bimzelx |
| Sandoz INC. | $26.02 | 2024 | Hyrimoz |
| Mimedx Group, INC. | $25.37 | 2025 | |
| Incyte Corporation | $23.38 | 2022 | |
| Organon LLC | $23.35 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.28 | 2024 | Spevigo |
| Teva Pharmaceuticals USA, INC. | $21.97 | 2024 | |
| Dermavant Sciences, INC. | $19.39 | 2024 | Vtama |
| Encore Dermatology INC. | $18.32 | 2019 | |
| Arcutis Biotherapeutics, INC. | $18.16 | 2023 | |
| Amgen INC. | $16.66 | 2021 | |
| Vyne Pharmaceuticals INC. | $16.39 | 2020 | |
| Sebela Pharmaceuticals INC. | $16.22 | 2023 | Naftin |
| Sun Pharmaceutical Industries INC. | $12.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Knisley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.